This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
=== Non-destructive sampling protocols === Although the ammonium bicarbonate protocol should not be considered a non-destructive method, it was followed by more 'true' non-destructive methods. The first of these was the eraser protocol, first tested on parchment, but later also applied to bone. The eraser protocol is performed by rubbing a PVC eraser on a piece of parchment or bone. The friction generates triboelectric forces, which causes small particles of the sample to cling to the eraser waste. From the eraser waste collagen can then be extracted and analysed. The eraser protocol was found to work relatively well for parchment, but it is less effective on bone. Additionally, it leaves microscopic traces on the bone surface, which appear very similar to use wear traces and could be an issue for use wear analysis. A second non-destructive protocol is the plastic bag protocol, first published in 2019. It is based on the idea that the normal friction between an object and the plastic bags, commonly used for storing archaeological objects, might be sufficient to extract enough material for ZooMS analysis. A third protocol uses the same triboelectric principle. However, instead of using an eraser, this microgrid protocol employs a fine polishing film to remove very small amounts of material from a sample. The last non-destructive protocol that has been published for ZooMS is the membrane box protocol. The membrane box protocol is based on contact electrification, which is the generation of electrostatic forces due to small localised differences in charge between two objects.
=== Differential diagnosis === Ullrich congenital muscular dystrophy (UCMD) involves mutations on the same genes as Bethlem myopathy, but has a more severe presentation, with the ability to walk (ambulation) typically being lost between the ages of 5–15 years. Autosomal recessive myosclerosis myopathy is allelic to the COL6A2 gene, it includes multiple contractures of the joints with slender muscles which are infiltrated by connective tissue and fibrosis, giving them a firm, "woody" feel upon palpitation. The symptoms of Bethlem myopathy may overlap with other conditions including Emery–Dreifuss muscular dystrophy, congenital muscular dystrophies, limb girdle muscular dystrophies, FHL1-related myopathies (X-linked myopathy with postural muscle atrophy, reducing body myopathy, and scapuloperoneal myopathy), and some forms of Ehlers–Danlos syndrome. Tubular aggregate myopathy (TAM1 & TAM2) includes, among other symptoms, contractures, muscle weakness, and fatty atrophy of muscle. Typical to Bethlem myopathy 1 and 2 are the presence of multiple contractures. A contracture can be caused by a variety of reasons, from disease to lifestyle (see Muscle contractures). If the patient lacks multiple contractures, as well as lacks other common symptoms of Bethlem myopathy, and in addition has muscular symptoms which are not known to be associated with Bethlem myopathy such as muscle hypertrophy, exercise-induced (dynamic) symptoms rather than fixed muscle weakness (static) symptoms, or cardiac involvement such as arrhythmia, then other myopathies should be considered.
==== Structural problems ==== Structurally, changes within the musculature in the intestine, such as increased elastin, can lead to increased frequency of herniation. Laxity of the phreno-esophageal and gastro-hepatic ligaments can lead to hiatal hernia, which in turn can lead to commonly reported symptoms such as acid reflux, abdominal pain, early satiety, and bloating. Internal organ prolapses and intestinal intussusceptions occur with greater frequency in patients with weakened connective tissues.
== Other == Combine car, or combine, a type of railroad car which combines sections for passengers and freight Combine painting, a type of artwork COMBINE, a computational biology initiative Combine (Half-Life), a fictional alien enemy force from the Half-Life video game series The Combine (group), an organized crime group The Combine (Australian film industry) Combine Music Group, a defunct music publisher
Sources: en.wikipedia.org
Hussein al-Houthi believed that the "last exemplary" Zaydi scholar and leader was Al-Hadi ila'l-Haqq Yahya; later Zaydi imams were regarded as having deviated from the original form of Islam. The Houthis' belief in the "Quranic Way" also includes the rejection of tafsir (Quranic interpretations) as being derivative and divisive, meaning that they have a low opinion of most existing Islamic theological and juridical schools, including Zaydi traditionalists based in Sanaa with whom they often clash. The Houthis claim that their actions are to fight against the alleged expansion of Salafism in Yemen and for the defence of their community from discrimination. The position of Saudi-backed Salafis and other Sunni groups in Yemen had steadily increased throughout the Republican era, as did the position of Sheikhs who sometimes cooperated with these Salafi groups for pragmatic reasons. The Salafis, who enjoyed considerable support from the Saleh regime, reportedly pursued an aggressive "policy of provocation" towards the Zaydis who inhabited the surrounding area, often accusing them of apostasy. In the years before the rise of the Houthi movement, state-supported Salafis had harassed Zaydis and destroyed Zaydi sites (most notably cemeteries) in Yemen. After their rise to power in 2014, the Houthis consequently "crushed" the Salafi community in Saada Governorate and mostly eliminated the al-Qaeda presence in the areas under their control; the Houthis view al-Qaeda as "Salafi jihadists" and thus "mortal enemies".
== See also == Angiogenesis Bone growth factor Cytokine Growth factor receptor Human Genome Organisation Mitogen Neurotrophic factor Receptor (biochemistry) Signal transduction Wound healing § Overview of involved growth factors
Historian Jacques Lévesque framed these changes within a pattern he termed "negotiated revolutions," distinguishing the top-down transitions engineered in Poland and Hungary from the popular uprisings that followed in East Germany, Czechoslovakia, and Romania, which for audiences across the bloc, signaled that the Brezhnev Doctrine was truly dead.
Seawater contains about 3.5% sodium chloride on average, plus smaller amounts of other substances. The physical properties of seawater differ from fresh water in some important respects. It freezes at a lower temperature (about −1.9 °C (28.6 °F)) and its density increases with decreasing temperature to the freezing point, instead of reaching maximum density at a temperature above freezing. The salinity of water in major seas varies from about 0.7% in the Baltic Sea to 4.0% in the Red Sea. (The Dead Sea, known for its ultra-high salinity levels of between 30 and 40%, is really a salt lake.) Tides are the cyclic rising and falling of local sea levels caused by the tidal forces of the Moon and the Sun acting on the oceans. Tides cause changes in the depth of the marine and estuarine water bodies and produce oscillating currents known as tidal streams. The changing tide produced at a given location is the result of the changing positions of the Moon and Sun relative to the Earth coupled with the effects of Earth rotation and the local bathymetry. The strip of seashore that is submerged at high tide and exposed at low tide, the intertidal zone, is an important ecological product of ocean tides.
Jacobson JB; Kaplan NO (1957). "A reduced pyridine nucleotide pyrophosphatase". J. Biol. Chem. 226 (1): 427–437. doi:10.1016/S0021-9258(18)64843-4. PMID 13428775. Kornberg A; Pricer WE (1950). "Nucleotide pyrophosphatase". J. Biol. Chem. 182 (2): 763–778. doi:10.1016/S0021-9258(18)56512-1. Kumar SA, Rao NA, Vaidyanathan CS (1965). "Nucleotidases in plants. I. Partial purification and properties of the enzyme hydrolyzing flavine adenine dinucleotide from mung bean seedlings (Phaseolus radiatus)". Arch. Biochem. Biophys. 111 (3): 646–52. doi:10.1016/0003-9861(65)90246-8. PMID 5862212. Swartz MN, Kaplan NO, Lamborg MF (1958). "A "heat-activated" diphosphopyridine nucleotide pyrophosphatase from Proteus vulgaris". J. Biol. Chem. 232 (2): 1051–1063. doi:10.1016/S0021-9258(19)77421-3. PMID 13549486.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.